Loading...
Market
Will FluMist nasal spray vaccine receive major safety warnings or recalls by end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements or AstraZeneca press releases
Story
FDA Approves First At-Home FluMist for Self- or Caregiver-Administration
Sep 20, 2024, 06:34 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration, making it the first influenza vaccine that can be administered at home without the need for a healthcare provider. The vaccine is approved for individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. This approval represents a significant step in broadening vaccination options and enhancing public health measures. Interested individuals will complete a screening and eligibility assessment through a third-party pharmacy.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%